The Trump administration is preparing an executive order to establish a board that would review and potentially reject National Institutes of Health (NIH) grant awards, according to reporting from multiple outlets. The move represents an effort to place ideological control over one of the world's largest public funders of biomedical research, breaking with the agency's traditional practice of evaluating proposals based on scientific merit alone.
Senior administration officials discussed the proposal during a Friday meeting, where they criticized the NIH for supporting what they characterized as "woke" initiatives misaligned with the president's political priorities. According to , Trump directed budget director Russell Vought to draft the executive order, which would give Vought direct authority over decisions affecting the NIH's congressionally appropriated funding.
The proposed board would include Vought, who heads the White House Office of Management and Budget (OMB), and NIH Director Jay Bhattacharya. According to reporting, the committee would be required to reach unanimous decisions on grant awards, effectively giving either member veto power over research funding decisions. The New York Times reported that internal tension over the plan had already created friction between Vought and Bhattacharya.
How would this change the NIH's grant process?
The NIH currently evaluates research proposals through a peer-review system in which scientists assess applications based on scientific quality, feasibility, and potential impact. The proposed board would insert political appointees directly into this process, allowing them to reject grants on ideological grounds rather than scientific merit. The New York Times reported that the White House had begun drafting the order after the contentious Friday meeting, with the new committee meant to review the NIH's vast research portfolio.
This represents a departure from how federal research funding has historically operated. The OMB is responsible for implementing the president's policies across the executive branch, but it has not traditionally held veto power over individual grant decisions at research agencies.
What research has already been affected?
The administration has already begun flagging and disrupting grants containing certain terminology. Since Trump took office for his second term, billions of dollars in federal grants related to health, nutrition, the environment, and disaster relief have been frozen or redirected. Research proposals containing words including "equity," "racist," "gender," and "climate change" have been flagged by the administration to hinder funding for scientific research.
Bhattacharya has publicly supported cuts to federal research spending and defended the NIH's grant-making process on Friday, while Vought has expressed a desire to reshape federal spending priorities across the government.
What legal challenges are emerging?
The NIH currently faces a lawsuit filed by researchers who argue that the Trump administration is hindering and terminating scientific grants to censor viewpoints opposing the president's ideological agenda. Researchers are accusing the administration of violating the First Amendment.
What the first amendment does not allow is the government's use of its funding power to target or silence the expression of disfavored viewpoints within the biomedical research community.
This legal challenge underscores broader concerns about using federal funding as a tool to suppress particular areas of scientific inquiry or research directions.
Why does this matter for American science?
The NIH distributes approximately $48 billion annually and is the world's largest public funder of biomedical research. Any structural change to its grant-review process carries unusually significant consequences for the direction of American scientific research and innovation. A board empowered to reject grants on political grounds could reshape which diseases receive research funding, which institutions attract federal support, and which scientific questions researchers pursue.
The proposal also follows a pattern of administration actions affecting federal science agencies. In April 2026, Trump terminated all members of the National Science Board overseeing the NSF, sparking concerns over US science funding and innovation. Additionally, RFK Jr has called for better Alzheimer's screening, but the USPSTF has been blocked from meeting for more than a year, slowing research and delaying guidance.
What is Congress saying?
Members of Congress are already pushing back on the plan to create a commission of political appointees to review NIH grants. According to Stat News, lawmakers have begun expressing opposition to the proposal, suggesting that oversight hearings or legislative resistance could follow if the executive order is finalized.
The Department of Health and Human Services, which oversees the NIH, and the White House did not immediately respond to requests for comment on the proposal.
What happens next?
The White House was drafting the executive order as of late September 2026, but no final issuance date had been announced. The order would need to be signed by the president before taking effect. Once finalized and implemented, the board structure would begin reviewing NIH grant decisions, potentially altering the distribution of federal research funding across American universities and research institutions. Congressional pushback may influence whether the order proceeds or faces legislative obstacles.
Key Facts:
- The proposed board would include OMB Director Russell Vought and NIH Director Jay Bhattacharya, with unanimous decision requirements giving either member veto power over grants
- The NIH distributes approximately $48 billion annually and is the world's largest public funder of biomedical research
- Grants have already been flagged or disrupted over terms such as "equity," "racist," "gender," and "climate change"
- Researchers have filed a lawsuit claiming the administration is violating the First Amendment by using funding power to silence disfavored viewpoints
- Congress is beginning to push back on the proposal, with potential oversight hearings or legislative resistance expected
